Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit, Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics announced presentations at the 2023 Cytokine-Based Drug Development Summit and provided a preliminary update on the SON-080 study in chemotherapy-induced peripheral neuropathy. Seven patients have been enrolled, and doses have been tolerated well. The Data Safety Monitoring Board is expected to meet in Q3 2023.
June 23, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics provided a positive preliminary update on the SON-080 study, with doses being well-tolerated. The Data Safety Monitoring Board is expected to meet in Q3 2023.
The positive preliminary update on the SON-080 study indicates that the drug is being well-tolerated by patients, which is a good sign for the company's ongoing research. The upcoming DSMB meeting in Q3 2023 will provide further insight into the safety and efficacy of the drug, potentially impacting the stock price positively.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100